Deal Details
Adaptas Sold to IMI
Summary
Adaptas Solutions, LLC (“Adaptas” or the “Company”), a portfolio company of Ampersand Capital Partners (“Ampersand”), has been acquired by IMI, plc (“IMI”) for $271 million. The transaction closed in December 2021.
Baird served as the exclusive financial advisor to Adaptas on this transaction.
About
Adaptas is a manufacturer of mission critical mass spectrometry subsystems and components, such as electron multipliers, filaments, power supplies and ion optic grids, as well as liquid handling and lab automation components. The Company is based in Palmer, Massachusetts and also has facilities in Pennsylvania, West Sussex in the United Kingdom, New South Wales in Australia, and Qidong in China.Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors.
IMI designs, manufactures and services highly engineered products that control the precise movement of fluids. IMI’s innovative technologies, built around valves and actuators, enable vital processes to operate safely, sustainably, cleanly, efficiently and cost effectively. IMI employs around 10,000 people, has manufacturing facilities in 18 countries and operates a global service network. IMI is listed on the London Stock Exchange.
CONTACT US TO LEARN MORE
- Date
- January 2022
- Company
- Adaptas Solutions, LLC
- Transaction
- M&A - Sellside
- Sectors
- Healthcare
- Verticals
-
Medical Technology
Test, Measurement & Automation
- Target Geography
- North America
- Acquiror Geography
- Europe
Share
